STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study tested a combination of two drugs, trametinib and docetaxel, in 60 people with advanced KRAS-mutant non-small cell lung cancer that had worsened after one or two prior treatments. The goal was to see if the combination could shrink tumors. Participants received both dr…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New combo therapy aims to zap spine tumors before they paralyze
Disease control OngoingThis study tests whether using heat (thermal ablation) followed by very precise radiation (stereotactic radiosurgery) can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with various solid tumors (like lung, breast, or prosta…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs, ceritinib and everolimus, given together to adults with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find a dose that controls tumor growth with manageable side eff…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has worsened after previous treatment. The main goal is to find the safest dose and understand side effects. About 36…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with low or high-dose radia…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests two drugs, erlotinib and cabozantinib, given alone or together in people with advanced non-small cell lung cancer that does not have a certain gene change (EGFR mutation). The goal is to see if the combination works better than either drug alone to slow cancer gr…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC